ORALE TESTOSTERON-TRIDECANOAT-THERAPIE

European patent · EP3548037 · Deleted

Register entry

Publication number
EP3548037
Application number
EP17876230
Kind
European patent with effect for Switzerland and Liechtenstein
Status
Deleted
Specification
Granted
Filed
Nov 30, 2017
Published
Oct 9, 2019
Granted
Jul 3, 2024
Deleted
Jun 25, 2025
Reason
Annual fee unpaid
IPC classes
A61K 31/568 (2006.01)
A61P 5/24 (2006.01)
A61K 9/48 (2006.01)
A61K 9/20 (2006.01)
Priority
US 201662428167 P 30.11.2016
US 201662428317 P 30.11.2016
PCT application
PCT/US2017/064083 30.11.2017
PCT publication
WO2018/102618 07.06.2018
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jun 25, 2025

    Deleted, fee unpaid

    Status of protective title
    Active → Cancelled
    Cancellation date
    25.06.2025
    Cause for cancellation
    Non-payment of renewal fee

    Published in Swissreg on 25.06.2025

  2. May 14, 2025

    Change

    Published in Swissreg on 14.05.2025

  3. Jul 3, 2024

    Granted

    Published in Swissreg on 03.07.2024

Parties

Holder

Lipocine Inc.

675 Arapeen Drive Suite 202, Salt Lake City, UT 84108, US

Inventor

KIM, Kilyoung

Salt Lake City, UT 84108, US

CHIDAMBARAM, Nachiappan

Salt Lake City, UT 84108, US

NACHAEGARI, Satish Kumar

Salt Lake City, UT 84108, US

PATEL, Mahesh V.

Salt Lake City, UT 84108, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.